Phase 3 TRIUMPH-4 showed 28.7% weight loss at 68 weeks, substantially exceeding CagriSema's 20.4% at 68 weeks
Lawsuits are already consolidated in federal and state courts, and deadlines may apply
Semaglutide can worsen diabetic eye disease (retinopathy), and in very rare cases it has been linked to sudden vision loss from a condition called non-arteritic anterior ischemic optic neuropathy (NAION)
However, too long a delay in bringing these drugs to an employer-sponsored plan could mean a disadvantage in recruitment and retention, as well as a decline in productivity and overall health of population
Diabetes and Ramadan: practical guidelines
[DOI] [PMC free article] [PubMed] [Google Scholar] 39.AlAshqar A., Patzkowsky K., Afrin S., Wild R., Taylor H.S., Borahay M.A